論文

査読有り 国際誌
2020年5月7日

Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.

Toxins
  • Takuhiro Matsumura
  • ,
  • Sho Amatsu
  • ,
  • Ryo Misaki
  • ,
  • Masahiro Yutani
  • ,
  • Anariwa Du
  • ,
  • Tomoko Kohda
  • ,
  • Kazuhito Fujiyama
  • ,
  • Kazuyoshi Ikuta
  • ,
  • Yukako Fujinaga

12
5
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3390/toxins12050302

Botulinum neurotoxin (BoNT) is the most potent natural toxin known. Of the seven BoNT serotypes (A to G), types A, B, E, and F cause human botulism. Treatment of human botulism requires the development of effective toxin-neutralizing antibodies without side effects such as serum sickness and anaphylaxis. In this study, we generated fully human monoclonal antibodies (HuMAbs) against serotype B BoNT (BoNT/B1) using a murine-human chimera fusion partner cell line named SPYMEG. Of these HuMAbs, M2, which specifically binds to the light chain of BoNT/B1, showed neutralization activity in a mouse bioassay (approximately 10 i.p. LD50/100 µg of antibody), and M4, which binds to the C-terminal of heavy chain, showed partial protection. The combination of two HuMAbs, M2 (1.25 µg) and M4 (1.25 µg), was able to completely neutralize BoNT/B1 (80 i.p. LD50) with a potency greater than 80 i.p. LD50/2.5 µg of antibodies, and was effective both prophylactically and therapeutically in the mouse model of botulism. Moreover, this combination showed broad neutralization activity against three type B subtypes, namely BoNT/B1, BoNT/B2, and BoNT/B6. These data demonstrate that the combination of M2 and M4 is promising in terms of a foundation for new human therapeutics for BoNT/B intoxication.

リンク情報
DOI
https://doi.org/10.3390/toxins12050302
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32392791
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291131
ID情報
  • DOI : 10.3390/toxins12050302
  • PubMed ID : 32392791
  • PubMed Central 記事ID : PMC7291131

エクスポート
BibTeX RIS